C-PJFV

FILE C-PJFV·COMPANY·CURATED BY ETERNAL SEARCH

NeuroNascent Inc (NNI)

oral small molecules, neurogenesis, neuron regeneration

replacementreplacingsmall molecule

neuronascent.com·Clarksville, Maryland, United States·$4M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-PJFV

Projects

Cajuvenate for canine cognitive dysfunction

exploratory

drug program · high · Thu Jan 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop the veterinary-use version of NNI-362 for Canine Cognitive Dysfunction and use an aged-CCD field trial to inform a go/no-go decision for proof-of-concept development.

Veterinary oral small-molecule neuron regenerative therapy; aged canine cognitive dysfunction field trial for go/no-go decision of an NNI-362 Phase 2 proof-of-concept trial.

Approximately $1 million Alzheimer's Association Part the Cloud grant listed for 'Aged CCD Field Trial for Go-no-go Decision of NNI-362 Ph2 POC Trial.'

NNI-351 Fragile X syndrome and Down syndrome program

undisclosed

drug program · medium

Develop a NeuroNascent pipeline candidate for developmental-delay indications including Fragile X syndrome and Down syndrome.

Pipeline-listed therapeutic candidate; specific intervention details and development stage were not provided in the supplied material.

Listed in NeuroNascent's pipeline as NNI-351 for Fragile X syndrome and Down syndrome.

NNI-362 neuron regenerative therapy

phase 1

drug program · high

Develop an orally available neuron regenerative therapy for Alzheimer's disease, Parkinson's disease, age-related disorders, and other chronic neurological disorders by promoting endogenous neuronal regeneration.

Oral small-molecule allosteric p70S6 kinase stimulator evaluated in a placebo-controlled, double-blind Phase 1a dose-escalation trial in healthy aged volunteers; plasma p-tau181 used as a pharmacodynamic biomarker in higher-dose arms.

Phase 1a human safety testing completed; 2025 publication reported safety, tolerability, pharmacokinetics, and p-tau181 pharmacodynamic findings, with Phase 2 studies warranted.

NNI-362 was reported safe and well tolerated in healthy older individuals. The two highest multiple-dose arms, 120 mg and 240 mg, significantly reduced plasma p-tau181 versus pretreatment levels, while placebo showed no change. Preclinical models reported reversal of cognitive and neural regenerative deficits in aging and disease models.

NNI-370 Parkinson's disease program

undisclosed

drug program · medium

Develop a NeuroNascent pipeline candidate for Parkinson's disease.

Pipeline-listed therapeutic candidate; specific intervention details and development stage were not provided in the supplied material.

Listed in NeuroNascent's pipeline as NNI-370 for Parkinson's disease.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

Cajuvenate for canine cognitive dysfunction

exploratory

drug program · high · Thu Jan 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop the veterinary-use version of NNI-362 for Canine Cognitive Dysfunction and use an aged-CCD field trial to inform a go/no-go decision for proof-of-concept development.

Veterinary oral small-molecule neuron regenerative therapy; aged canine cognitive dysfunction field trial for go/no-go decision of an NNI-362 Phase 2 proof-of-concept trial.

Approximately $1 million Alzheimer's Association Part the Cloud grant listed for 'Aged CCD Field Trial for Go-no-go Decision of NNI-362 Ph2 POC Trial.'

NNI-351 Fragile X syndrome and Down syndrome program

undisclosed

drug program · medium

Develop a NeuroNascent pipeline candidate for developmental-delay indications including Fragile X syndrome and Down syndrome.

Pipeline-listed therapeutic candidate; specific intervention details and development stage were not provided in the supplied material.

Listed in NeuroNascent's pipeline as NNI-351 for Fragile X syndrome and Down syndrome.

NNI-362 neuron regenerative therapy

phase 1

drug program · high

Phase 1a human safety testing completed; 2025 publication reported safety, tolerability, pharmacokinetics, and p-tau181 pharmacodynamic findings, with Phase 2 studies warranted.

NNI-370 Parkinson's disease program

undisclosed

drug program · medium

Develop a NeuroNascent pipeline candidate for Parkinson's disease.

Pipeline-listed therapeutic candidate; specific intervention details and development stage were not provided in the supplied material.

Listed in NeuroNascent's pipeline as NNI-370 for Parkinson's disease.